Pipeline Overview*
Pipeline Overview*
| Drug** | Indication | Pre-clinical | Phase 1/2 | Phase 3 | Approved | |
|---|---|---|---|---|---|---|
| RHB-204 | NTM infections | Phase 3 U.S. study |
||||
| RHB-104 | Crohn's disease | Positive top-line results from Phase 3 MAP U.S. study |
||||
| RHB-102 (Bekinda®) |
Gastroenteritis & gastritis | Positive results from Phase 3 U.S. study |
||||
| IBS-D | Positive results from Phase 2 U.S. study |
|||||
| RHB-106 | Bowel cleanser | Phase 2/3 studies planned |
||||
| Opaganib (Yeliva®) |
Oncology indications and COVID-19 | Ongoing Phase 2/3 COVID-19 & Phase 2 Oncology Program |
||||
| RHB-107 upamostat |
Oncology/GI and COVID-19 | COVID-19, GI, inflammatory & oncology indications |
||||
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies**RHB-102 (Bekinda®) and Opaganib (Yeliva®) are proposed tradenames which are subject to FDA review and approval.
